Hospital

Inhibiting Toll-like receptor 4 stopped it from accumulating cisplatin, thereby halting the hearing damage caused by the cancer treatment.

The researchers are hopeful this could eventually lead to the elimination of long-term antiretroviral treatment as a lifelong necessity for patients with HIV.

As more companies enter this space, expect competition to further lower prices while improving quality.

No cases of COVID-19 were observed in the vaccine group using the case definition from the adult phase 3 COVE study, compared to 4 cases in the placebo group.

Support groups and patient care clinics have been created to help patients who suffer from lasting effects of the virus.

The basal subtype of ductal adenocarcinoma can be identified by the presence of the DeltaNp63 protein.

Program participants had 55% fewer hospitalizations, 45% fewer emergency department visits, and shorter hospital stays by 1 day in the 30 days after study entry.

The objective of the study was to determine whether atezolizumab could also be efficacious for patients with earlier-stage disease who may be at risk of disease recurrence following surgery

A recent study found that nearly 3% of insured adults in the United States under the age of 65 years take medications that weaken their immune system.

Addressing the underlying causes of pharmacist burnout is essential, according to Melissa Santibañez, PharmD, BCCCP, a critical care clinical pharmacist at Memorial Regional Hospital.

FDA approval of 2-drug injectable Cabenuva is a game changer in maintaining viral suppression in patients.

Occupational exposure to certain medications and long hours standing may increase risk.

The study authors sought to examine the risks of subsequent primary cancers (SPCs) among breast cancer survivors by HR status and age at diagnosis.

Researchers found no evidence of abnormal blood flow between the mother and fetus or problems with fetal blood flow following COVID-19 vaccination.

Although there is no single playbook that works for all types of practices, some combinations of practice characteristics and operational changes can help practices address cardiovascular disease.

In a trial of amivantamab-vmjw, investigators found an overall response rate of 40% among patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations.

Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer

The safety profile for the combination treatment remained consistent with previously reported data in NSCLC and was deemed manageable with established protocols with no new safety signals identified.

Final data from a phase 3 trial assessing evolocumab in patients with HIV who have high cholesterol confirmed the safety and efficacy of the drug as a treatment.

Although the opioid epidemic is a broad societal problem, health systems can play a critical role in the response.

When a patient recovering from gonorrhea was fed the powder of the kuchila molung plant, the patient quickly suffered from much more than painful urination.

Median disease-free survival was twice as long in patients who received nivolumab compared to patients who received a placebo.

Locally advanced head and neck cancer represents a group of diseases that have seen few new treatment options over the past 20-plus years

The percentage dropped to only about 25% among people at a low genetic risk for the disease.

Melanoma forms when pigment-producing cells called melanocytes mutate and multiply uncontrollably.

It is important for pharmacists to understand the relationship between medication adherence and patient outcomes.

Recent surveys have found high rates of occupational burnout among hematology and oncology pharmacists, with more than half or survey respondents reporting burnout.

Matthew Harms, a medical consultant and care center director at the MDA and associate professor of neurology at Columbia University Medical Center, to discuss new treatments and anticipated developments for ALS over the next year.

The primary endpoint of organ failure or death was 11.2% for those receiving dapagliflozin compared to 13.8% for those receiving the placebo.

A combination immunotherapy of interleukin-21 (IL-21) and interferon alpha (IFN-alpha) in combination with antiretroviral therapy (ART) is effective in generating highly functional natural killer (NK) cells that can help control and reduce simian immunodeficiency virus (SIV) in animal models.